Veracyte, Inc.(VCYT)Earnings, Financials & Key Ratios

VCYT•NASDAQ

$41.19

$3.29B mkt cap·50.2× P/E·Price updated May 6, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryDiagnostics and Omics Tools

AboutVeracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.Show more

Revenue$517M+16.0%
EBITDA$96M+141.3%
Net Income$66M+174.9%
EPS (Diluted)0.82+164.5%
Gross Margin69.62%+4.1%
EBITDA Margin18.48%+108.0%
Operating Margin14.34%+296.0%
Net Margin12.83%+136.9%
ROE5.34%+145.5%
ROIC5.63%+325.3%
Debt/Equity0.03-29.8%

Technical→

VCYT Key Insights

Veracyte, Inc. (VCYT) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Company is almost debt free
✓Strong Piotroski F-Score: 8/9
✓FCF machine: 24.5% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 34.5%

✗Weaknesses

✗Weak 3Y average ROE of 0.2%

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

VCYT Price & Volume

Veracyte, Inc. (VCYT) stock price & volume — 10-year historical chart

Loading chart...

VCYT Growth Metrics

Veracyte, Inc. (VCYT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years26.44%

5 Years34.5%

3 Years20.37%

TTM16.91%

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM166.31%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM164.09%

Return on Capital

10 Years-13.13%

5 Years-2.99%

3 Years-0.27%

Last Year5.78%

VCYT Recent Earnings

Veracyte, Inc. (VCYT) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 12/12 qtrs (100%)●Beat Revenue 10/12 qtrs (83%)

Q2 2026Latest

May 5, 2026

EPS

$0.52

Est $0.34

+52.9%

Revenue

$139M

Est $130M

+6.7%

Q1 2026

Feb 25, 2026

EPS

$0.53

Est $0.41

+29.8%

Revenue

$141M

Est $136M

+3.6%

Q4 2025

Nov 4, 2025

EPS

$0.51

Est $0.32

+59.4%

Revenue

$132M

Est $136M

-2.9%

Q3 2025

Aug 6, 2025

EPS

$0.44

Est $0.31

+41.9%

Revenue

$130M

Est $124M

+4.7%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	May 5, 2026	$0.52vs $0.34+52.9%	$139Mvs $130M+6.7%
Q1 2026	Feb 25, 2026	$0.53vs $0.41+29.8%	$141Mvs $136M+3.6%
Q4 2025	Nov 4, 2025	$0.51vs $0.32+59.4%	$132Mvs $136M-2.9%
Q3 2025	Aug 6, 2025	$0.44vs $0.31+41.9%	$130Mvs $124M+4.7%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	Debt / Equity
EXASExact Sciences CorporationDirect Competitor	20.02B	104.91	-95.37	17.69%	-6.4%	-8.66%	1.05
NTRANatera, Inc.Direct Competitor	29.58B	215.09	-140.58	56.75%	-14.61%	-24.69%	0.16
CDNACareDx, IncDirect Competitor	1.08B	20.94	-52.35	13.79%	-1.98%	-2.61%	0.06
ACNBACNB CorporationDirect Competitor	551.12M	53.23	14.79	28.89%		9.2%	0.78
PAHCPhibro Animal Health CorporationDirect Competitor	2.38B	58.64	49.28	27.37%	6.29%	30.81%	2.67
ILMNIllumina, Inc.Product Competitor	21.66B	142.58	26.16	-0.78%	19.43%	32.84%	0.94
TMOThermo Fisher Scientific Inc.Product Competitor	175.76B	472.95	26.66	3.91%	15.18%	13.23%	0.76
HOLXHologic, Inc.Product Competitor	16.97B	76.01	30.53	1.74%	13.18%	10.37%	0.52

Compare VCYT vs Peers

Veracyte, Inc. (VCYT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs EXAS

Most directly comparable listed peer for VCYT.

Scale Benchmark

vs TMO

Larger-name benchmark to compare VCYT against a more recognizable public peer.

Peer Set

Compare Top 5

vs EXAS, NTRA, CDNA, ACNB

VCYT Income Statement

Veracyte, Inc. (VCYT) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Sales/Revenue	71.95M	92.01M	120.37M	117.48M	219.51M	296.54M	361.05M	445.76M	517.14M	541.74M
Revenue Growth %	10.55%	27.87%	30.82%	-2.4%	86.85%	35.09%	21.76%	23.46%	16.01%	16.91%
Cost of Goods Sold	28.2M	33.08M	36.52M	41.45M	74.4M	101.58M	112.9M	147.62M	157.1M	154.85M
COGS % of Revenue	39.19%	35.95%	30.34%	35.29%	33.89%	34.26%	31.27%	33.12%	30.38%	-
Gross Profit	43.76M▲ 0%	58.93M▲ 34.7%	83.84M▲ 42.3%	76.03M▼ 9.3%	145.11M▲ 90.9%	194.95M▲ 34.3%	248.15M▲ 27.3%	298.14M▲ 20.1%	360.05M▲ 20.8%	386.89M▲ 0%
Gross Margin %	60.81%	64.05%	69.66%	64.71%	66.11%	65.74%	68.73%	66.88%	69.62%	71.42%
Gross Profit Growth %	10.44%	34.67%	42.28%	-9.32%	90.87%	34.35%	27.29%	20.15%	20.76%	-
Operating Expenses	70.3M	81.16M	98.97M	111.42M	227.02M	236.03M	333.94M	282M	285.89M	320.05M
OpEx % of Revenue	97.7%	88.21%	82.22%	94.84%	103.42%	79.6%	92.49%	63.26%	55.28%	-
Selling, General & Admin	55.35M	65.28M	82.72M	89.12M	181.19M	174.08M	184.23M	206.04M	210.95M	202.62M
SG&A % of Revenue	76.92%	70.95%	68.72%	75.86%	82.54%	58.7%	51.03%	46.22%	40.79%	-
Research & Development	13.88M	14.82M	14.85M	17.2M	29.84M	40.6M	57.3M	69.29M	70.81M	80.19M
R&D % of Revenue	19.29%	16.11%	12.34%	14.64%	13.59%	13.69%	15.87%	15.54%	13.69%	-
Other Operating Expenses	476K	1.2M	1.4M	5.09M	15.98M	21.35M	92.41M	6.67M	4.13M	3M
Operating Income	-26.54M▲ 0%	-22.23M▲ 16.2%	-15.13M▲ 32.0%	-35.39M▼ 133.9%	-81.9M▼ 131.4%	-41.08M▲ 49.8%	-85.8M▼ 108.8%	16.14M▲ 118.8%	74.15M▲ 359.4%	66.26M▲ 0%
Operating Margin %	-36.88%	-24.16%	-12.57%	-30.12%	-37.31%	-13.85%	-23.76%	3.62%	14.34%	12.23%
Operating Income Growth %	7.86%	16.22%	31.96%	-133.95%	-131.44%	49.84%	-108.84%	118.81%	359.36%	-
EBITDA	-22.7M	-18.31M	-11.01M	-27.45M	-60.68M	-11.83M	-58.61M	39.6M	95.56M	82.32M
EBITDA Margin %	-31.54%	-19.9%	-9.15%	-23.36%	-27.64%	-3.99%	-16.23%	8.88%	18.48%	15.19%
EBITDA Growth %	10.26%	19.32%	39.88%	-149.27%	-121.09%	80.5%	-395.28%	167.57%	141.32%	75.39%
D&A (Non-Cash Add-back)	3.84M	3.92M	4.12M	7.94M	21.23M	29.25M	27.19M	23.46M	21.41M	16.05M
EBIT	-27.6M	-21.04M	-11.92M	-34.68M	-81.41M	-36.23M	-76.6M	25.75M	68.2M	60.77M
Net Interest Income	-4.94M	-1.96M	2.35M	365K	-106K	1.77M	7.33M	11.15M	0	6.42M
Interest Income	0	0	3.02M	594K	135K	1.97M	7.34M	11.15M	0	6.42M
Interest Expense	4.94M	1.96M	677K	229K	241K	198K	15K	2K	0	0
Other Income/Expense	-4.46M	-766K	2.53M	480K	254K	4.65M	9.18M	9.6M	-5.95M	24.48M
Pretax Income	-31M▲ 0%	-23M▲ 25.8%	-12.6M▲ 45.2%	-34.91M▼ 177.1%	-81.65M▼ 133.9%	-36.43M▲ 55.4%	-76.61M▼ 110.3%	25.74M▲ 133.6%	68.2M▲ 164.9%	90.75M▲ 0%
Pretax Margin %	-43.09%	-25%	-10.47%	-29.71%	-37.2%	-12.28%	-21.22%	5.78%	13.19%	16.75%
Income Tax	0	0	0	0	-6.09M	133K	-2.21M	1.61M	1.85M	2.73M
Effective Tax Rate %	0%	0%	0%	0%	7.45%	-0.37%	2.88%	6.24%	2.71%	3.01%
Net Income	-31M▲ 0%	-23M▲ 25.8%	-12.6M▲ 45.2%	-34.91M▼ 177.1%	-75.56M▼ 116.5%	-36.56M▲ 51.6%	-74.4M▼ 103.5%	24.14M▲ 132.4%	66.35M▲ 174.9%	88.01M▲ 0%
Net Margin %	-43.09%	-25%	-10.47%	-29.71%	-34.42%	-12.33%	-20.61%	5.42%	12.83%	16.25%
Net Income Growth %	1.13%	25.82%	45.22%	-177.08%	-116.46%	51.62%	-103.51%	132.44%	174.89%	166.31%
Net Income (Continuing)	-31M	-23M	-12.6M	-34.91M	-75.56M	-36.56M	-74.4M	24.14M	66.35M	88.01M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)	-0.91▲ 0%	-0.62▲ 31.9%	-0.27▲ 56.5%	-0.66▼ 144.4%	-1.11▼ 68.2%	-0.51▲ 54.1%	-1.02▼ 100.0%	0.31▲ 130.4%	0.82▲ 164.5%	1.08▲ 0%
EPS Growth %	16.51%	31.87%	56.45%	-144.44%	-68.18%	54.05%	-100%	130.39%	164.52%	164.09%
EPS (Basic)	-0.91	-0.62	-0.27	-0.66	-1.11	-0.51	-1.02	0.32	0.84	-
Diluted Shares Outstanding	33.93M	37.02M	46.14M	53.24M	67.89M	71.55M	72.64M	78.16M	80.57M	81.31M
Basic Shares Outstanding	33.93M	37.02M	46.14M	53.24M	67.89M	71.55M	72.64M	76.48M	78.58M	79.54M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

VCYT Balance Sheet

Veracyte, Inc. (VCYT) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Total Current Assets	53.93M	96.95M	187.69M	375.68M	243.1M	248.64M	285.62M	372.27M	488.38M	522.17M
Cash & Short-Term Investments	33.89M	78M	159.32M	349.36M	177.16M	178.85M	216.45M	289.44M	412.89M	439.06M
Cash Only	33.89M	78M	159.32M	349.36M	173.2M	154.25M	216.45M	239.09M	362.58M	263.14M
Short-Term Investments	0	0	0	0	3.96M	24.61M	0	50.35M	50.31M	175.92M
Accounts Receivable	12.72M	13.17M	19.33M	18.46M	41.46M	44.02M	40.38M	46.52M	44.66M	50.11M
Days Sales Outstanding	64.51	52.24	58.61	57.36	68.94	54.18	40.82	38.1	31.52	32.58
Inventory	5.32M	3.4M	6.81M	4.66M	11.22M	14.29M	16.13M	21.75M	20.55M	0
Days Inventory Outstanding	68.92	37.54	68.02	41	55.07	51.36	52.14	53.78	47.74	38.83
Other Current Assets	2M	0	0	0	-3.96M	11.47M	12.66M	14.55M	10.28M	33M
Total Non-Current Assets	24.74M	23.69M	87.53M	81.48M	944.72M	907.79M	829.28M	927.77M	917.64M	914.23M
Property, Plant & Equipment	9.69M	8.94M	17.74M	16.83M	31.14M	30.86M	30.86M	71.14M	58.79M	58.52M
Fixed Asset Turnover	7.43x	10.29x	6.78x	6.98x	7.05x	9.61x	11.70x	6.27x	8.80x	9.39x
Goodwill	1.06M	1.06M	2.73M	2.73M	707.9M	695.89M	702.98M	745.8M	767.15M	767.15M
Intangible Assets	13.07M	12M	65.02M	59.92M	202.73M	174.87M	88.59M	102.3M	89.15M	85.86M
Long-Term Investments	603K	603K	0	0	0	0	0	0	0	1.64M
Other Non-Current Assets	929K	1.69M	2.04M	2M	2.95M	6.17M	6.85M	8.53M	2.55M	9.47M
Total Assets	78.67M▲ 0%	120.64M▲ 53.3%	275.21M▲ 128.1%	457.16M▲ 66.1%	1.19B▲ 159.8%	1.16B▼ 2.6%	1.11B▼ 3.6%	1.3B▲ 16.6%	1.41B▲ 8.2%	1.44B▲ 0%
Asset Turnover	0.91x	0.76x	0.44x	0.26x	0.18x	0.26x	0.32x	0.34x	0.37x	0.39x
Asset Growth %	-22.14%	53.35%	128.13%	66.11%	159.83%	-2.64%	-3.59%	16.6%	8.15%	33.52%
Total Current Liabilities	12.03M	13.06M	17.47M	16.78M	64.15M	62.61M	61.24M	78.63M	59.94M	56.12M
Accounts Payable	3.85M	2.52M	2.33M	3.12M	12.36M	11.91M	12.94M	8.63M	4.59M	6.91M
Days Payables Outstanding	49.88	27.76	23.27	27.44	60.64	42.8	41.84	21.35	10.67	16.77
Short-Term Debt	0	1.36M	0	0	1.13M	0	0	0	4.05M	4.35M
Deferred Revenue (Current)	0	0	0	371K	4.65M	2.61M	2.01M	1.67M	1.16M	3.78M
Other Current Liabilities	0	0	10.1M	9.2M	33.7M	36.88M	29.19M	47.59M	50.13M	44.11M
Current Ratio	4.48x	7.42x	10.74x	22.39x	3.79x	3.97x	4.66x	4.73x	8.15x	8.15x
Quick Ratio	4.04x	7.16x	10.35x	22.11x	3.61x	3.74x	4.40x	4.46x	7.81x	7.81x
Cash Conversion Cycle	83.55	62.01	103.36	70.92	63.37	62.75	51.12	70.53	68.59	54.64
Total Non-Current Liabilities	29.42M	27.82M	18.29M	19.15M	27.16M	18.61M	9.56M	45.44M	36.51M	35.88M
Long-Term Debt	24.94M	23.93M	694K	810K	0	0	0	0	0	34.99M
Capital Lease Obligations	308K	0	11.51M	9.92M	14.1M	10.65M	7.53M	43.24M	35.6M	116.01M
Deferred Tax Liabilities	0	0	0	0	5.59M	4.53M	734K	1.23M	646K	3.8M
Other Non-Current Liabilities	4.17M	3.9M	6.09M	7.59M	7.13M	3.43M	1.3M	972K	257K	2.18M
Total Liabilities	41.44M	40.88M	35.76M	35.93M	91.31M	81.22M	70.8M	124.07M	96.44M	91.99M
Total Debt	25.25M	25.28M	13.61M	12.32M	18.85M	14.72M	12.63M	50.74M	39.65M	39.33M
Net Debt	-8.64M	-52.71M	-145.71M	-337.05M	-154.34M	-139.53M	-203.82M	-188.35M	-322.92M	-223.8M
Debt / Equity	0.68x	0.32x	0.06x	0.03x	0.02x	0.01x	0.01x	0.04x	0.03x	0.03x
Debt / EBITDA	-	-	-	-	-	-	-	1.28x	0.41x	0.48x
Net Debt / EBITDA	-	-	-	-	-	-	-	-4.76x	-3.38x	-3.38x
Interest Coverage	-5.59x	-10.72x	-17.61x	-151.44x	-337.79x	-182.97x	-5106.47x	12873.00x	-	-
Total Equity	37.23M▲ 0%	79.75M▲ 114.3%	239.46M▲ 200.2%	421.23M▲ 75.9%	1.1B▲ 160.3%	1.08B▼ 1.9%	1.04B▼ 2.9%	1.18B▲ 12.6%	1.31B▲ 11.4%	1.34B▲ 0%
Equity Growth %	-37.52%	114.25%	200.24%	75.91%	160.31%	-1.94%	-2.89%	12.63%	11.36%	38.63%
Book Value per Share	1.10	2.15	5.19	7.91	16.15	15.03	14.37	15.05	16.25	16.53
Total Shareholders' Equity	37.23M	79.75M	239.46M	421.23M	1.1B	1.08B	1.04B	1.18B	1.31B	1.34B
Common Stock	34K	41K	50K	58K	71K	72K	73K	78K	79K	80K
Retained Earnings	-211.09M	-234.09M	-246.69M	-281.59M	-357.16M	-393.72M	-468.12M	-443.98M	-377.63M	-348.92M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-9.3M	-12.01M	0	0	-15.08M	-31.35M	-24.02M	-36.09M	-8.21M	-8.22M
Minority Interest	0	0	0	0	0	0	0	0	0	0

VCYT Cash Flow Statement

Veracyte, Inc. (VCYT) cash flow — operating, investing & free cash flow history

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Cash from Operations	-23.91M	-13.52M	-3.23M	-9.71M	-31.62M	7.54M	44.22M	75.1M	136.31M	136.31M
Operating CF Margin %	-33.24%	-14.7%	-2.69%	-8.27%	-14.41%	2.54%	12.25%	16.85%	26.36%	-
Operating CF Growth %	14.53%	43.46%	76.1%	-200.46%	-225.62%	123.83%	486.89%	69.82%	81.51%	734.17%
Net Income	-31M	-23M	-12.6M	-34.91M	-75.56M	-36.56M	-74.4M	24.14M	66.35M	88.01M
Depreciation & Amortization	3.84M	3.92M	4.12M	7.94M	19.59M	25.93M	27.19M	23.46M	21.41M	21.48M
Stock-Based Compensation	6.62M	5.96M	9.81M	12.99M	22.52M	26.73M	33.14M	36.25M	43.6M	45.4M
Deferred Taxes	12K	0	-23K	0	-6.26M	133K	-3.84M	-233K	-581K	-606K
Other Non-Cash Items	2.06M	251K	312K	4.74M	3.87M	7.68M	66.3M	12.8M	7.82M	-9.24M
Working Capital Changes	-5.44M	-651K	-4.85M	-481K	4.22M	-16.38M	-4.16M	-21.32M	-2.3M	13.08M
Change in Receivables	-3.96M	-452K	-6.16M	955K	-8.57M	-4.5M	3.89M	-6.41M	-708K	778K
Change in Inventory	-1.85M	1.92M	-3.4M	1.06M	-1.46M	-3.01M	-1.69M	-5.87M	-2.86M	-563K
Change in Payables	1.73M	-1.57M	-141K	711K	5.16M	152K	-134K	-4.3M	-1.04M	-5.57M
Cash from Investing	-1.2M	-1.87M	-42.73M	-3.84M	-739.21M	-29.39M	15.11M	-56.27M	-9.21M	-85.35M
Capital Expenditures	-1.75M	-1.87M	-2.76M	-2.84M	-5.38M	-8.55M	-9.96M	-11.29M	-9.68M	-10.82M
CapEx % of Revenue	2.44%	2.04%	2.29%	2.41%	2.45%	2.88%	2.76%	2.53%	1.87%	-
Acquisitions	440K	0	-40M	0	-736.83M	0	0	5.01M	-2.85M	-2.85M
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	560K	0	23K	0	-162.42M	0	0	0	0	51.06M
Cash from Financing	-218K	59.5M	127.29M	203.59M	596.32M	3.49M	2.84M	4.9M	-4.22M	-4.37M
Debt Issued (Net)	-2.31M	-292K	-25.21M	-100K	0	-1.28M	0	0	0	0
Equity Issued (Net)	200K	55.04M	137.85M	193.83M	593.82M	0	0	19.99M	14.08M	9.3M
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0	0	0	0
Other Financing	1.9M	4.75M	14.65M	9.86M	2.5M	4.78M	2.84M	-15.09M	-18.3M	-13.67M
Net Change in Cash	-25.33M▲ 0%	44.1M▲ 274.1%	81.32M▲ 84.4%	190.05M▲ 133.7%	-176.02M▼ 192.6%	-18.95M▲ 89.2%	62.33M▲ 428.9%	23.3M▼ 62.6%	123.59M▲ 430.4%	77.05M▲ 0%
Free Cash Flow	-25.67M▲ 0%	-15.39M▲ 40.0%	-5.99M▲ 61.1%	-12.55M▼ 109.6%	-37M▼ 194.8%	-1.01M▲ 97.3%	34.26M▲ 3478.8%	63.81M▲ 86.2%	126.63M▲ 98.5%	154.81M▲ 0%
FCF Margin %	-35.68%	-16.73%	-4.97%	-10.68%	-16.85%	-0.34%	9.49%	14.31%	24.49%	28.58%
FCF Growth %	20.26%	40.03%	61.1%	-109.55%	-194.84%	97.26%	3478.8%	86.24%	98.45%	97.33%
FCF per Share	-0.76	-0.42	-0.13	-0.24	-0.54	-0.01	0.47	0.82	1.57	1.57
FCF Conversion (FCF/Net Income)	0.77x	0.59x	0.26x	0.28x	0.42x	-0.21x	-0.59x	3.11x	2.05x	1.76x
Interest Paid	2.72M	1.55M	332K	13K	9K	9K	0	0	0	0
Taxes Paid	21K	79K	35K	112K	112K	570K	1.7M	2.24M	0	1.43M

VCYT Key Ratios

Veracyte, Inc. (VCYT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM
Return on Equity (ROE)	-64.05%	-39.32%	-7.89%	-10.57%	-9.96%	-3.37%	-7.02%	2.17%	5.34%	6.86%
Return on Invested Capital (ROIC)	-73.1%	-59.96%	-18.79%	-29.83%	-11.97%	-3.28%	-7.25%	1.32%	5.63%	5.63%
Gross Margin	60.81%	64.05%	69.66%	64.71%	66.11%	65.74%	68.73%	66.88%	69.62%	71.42%
Net Margin	-43.09%	-25%	-10.47%	-29.71%	-34.42%	-12.33%	-20.61%	5.42%	12.83%	16.25%
Debt / Equity	0.68x	0.32x	0.06x	0.03x	0.02x	0.01x	0.01x	0.04x	0.03x	0.03x
Interest Coverage	-5.59x	-10.72x	-17.61x	-151.44x	-337.79x	-182.97x	-5106.47x	12873.00x	-	-
FCF Conversion	0.77x	0.59x	0.26x	0.28x	0.42x	-0.21x	-0.59x	3.11x	2.05x	1.76x
Revenue Growth	10.55%	27.87%	30.82%	-2.4%	86.85%	35.09%	21.76%	23.46%	16.01%	16.91%

VCYT SEC Filings & Documents

Veracyte, Inc. (VCYT) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

May 5, 2026·SEC

Material company update

Mar 16, 2026·SEC

Material company update

Feb 25, 2026·SEC

10-K Annual Reports

FY 2026

Feb 26, 2026·SEC

FY 2025

Feb 28, 2025·SEC

10-Q Quarterly Reports

FY 2026

May 6, 2026·SEC

FY 2025

Nov 5, 2025·SEC

FY 2025

Aug 7, 2025·SEC

VCYT Frequently Asked Questions

Veracyte, Inc. (VCYT) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Veracyte, Inc. (VCYT) reported $541.7M in revenue for fiscal year 2025. This represents a 20382% increase from $2.6M in 2011.

Veracyte, Inc. (VCYT) grew revenue by 16.0% over the past year. This is strong growth.

Yes, Veracyte, Inc. (VCYT) is profitable, generating $88.0M in net income for fiscal year 2025 (12.8% net margin).

Dividend & Returns

Veracyte, Inc. (VCYT) has a return on equity (ROE) of 5.3%. This is below average, suggesting room for improvement.

Veracyte, Inc. (VCYT) generated $154.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More VCYT

Veracyte, Inc. (VCYT) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

Veracyte, Inc.(VCYT)Earnings, Financials & Key Ratios

VCYT Key Insights

✓Strengths

✗Weaknesses

VCYT Price & Volume

VCYT Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

VCYT Recent Earnings

VCYT Peer Comparison

Compare VCYT vs Peers

vs EXAS

vs TMO

Compare Top 5

VCYT Income Statement

VCYT Balance Sheet

VCYT Cash Flow Statement

VCYT Key Ratios

VCYT SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

VCYT Frequently Asked Questions

Explore More VCYT

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation